Local Adaptation of Cost Effectiveness Model for Apixaban Atrial Fibrillation Indication - Venezuela

Bristol-Myers Squibb80 enrolled

Overview

To characterize treatment patterns and healthcare resource utilization among adults diagnosed with non-valvular atrial fibrillation (NVAF) from the private setting in Venezuela.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Non-Valvular Atrial Fibrillation

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with diagnosis of AF (incident and prevalent cases) * Patient with at least 18 years * Patients enrolment before and during the study period * Patients treated in Venezuela Exclusion Criteria: * Women who were pregnant at any moment during the study period

Outcomes

Primary Outcomes

Frequency of Hospitalization

Time frame: approximately 2 years after enrollment

Duration of Hospitalization

Time frame: approximately 2 years after enrollment

Frequency of Outpatient visits

Time frame: approximately 2 years after enrollment

Secondary Outcomes

Incidence of Cerebrovascular Disease (CVD)

Time frame: Up to 3 years

Frequency of Hospitalization due to Cerebrovascular Disease (CVD)

Time frame: Up to 3 years

Duration of Hospitalization due to Cerebrovascular Disease (CVD)

Time frame: Up to 3 years

Frequency of Outpatient Visits due to Cerebrovascular Disease (CVD)

Time frame: Up to 3 years

Incidence of Acute Myocardial Infarction (AMI)

Time frame: Up to 3 years

Frequency of Hospitalization due to Acute Myocardial Infarction (AMI)

Time frame: Up to 3 years

Duration of Hospitalization due to Acute Myocardial Infarction (AMI)

Time frame: Up to 3 years

Frequency of Outpatient Visits due to Acute Myocardial Infarction (AMI)

Time frame: Up to 3 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.